The central nervous system is a potential reservoir and possible origin of drug resistance in hepatitis B infection.
Cerebrospinal fluid
HBV
Mutation
Sequence
Journal
Journal of virus eradication
ISSN: 2055-6640
Titre abrégé: J Virus Erad
Pays: England
ID NLM: 101654142
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
15
08
2023
accepted:
06
09
2023
medline:
29
9
2023
pubmed:
29
9
2023
entrez:
29
9
2023
Statut:
epublish
Résumé
The significance of hepatitis B virus (HBV) in cerebrospinal fluid (CSF) is unclear. Synchronous serum and CSF samples were collected from 13 patients. HBV DNA, full-length genome, quasispecies, phylogenetic tree, compartmentalization and mutation of the reverse transcriptase (RT) region were performed based on PCR and sequencing methods. HBV DNA was detected in the CSF of 3 antiviral-naïve individuals and 1 individual after successful antiviral therapy. Complete full-length HBV genomes were isolated from the CSF of 5 individuals, including 2 with undetectable serum HBV DNA. Ten individuals exhibited distinct CSF-serum quasispecies, 8 harbored independent CSF-serum genetic compartmentalization and phylogenetic trees, and 5 lamivudine/entecavir-associated resistance mutations only in the CSF. The frequencies of rtL180M and rtM204I/V mutations in both serum and CSF were higher in HIV-HBV-coinfected individuals than in the HBV-monoinfected ones (serum: rtL180M: 3.9% vs. 0, P = 0.004; rtM204I/V: 21.3% vs. 0, P < 0.001; CSF: rtL180M: 7.6% vs. 0, P = 0.026; rtM204I/V 7.6% vs. 1.6%, P = 0.097). CSF is a potential HBV reservoir, and HBV in CSF harbors distinct evolution and mutation characteristics from those in serum. HIV infection increases the possibility of HBV rtL180M and rtM204I/V mutations in both serum and CSF.
Sections du résumé
Background
UNASSIGNED
The significance of hepatitis B virus (HBV) in cerebrospinal fluid (CSF) is unclear.
Methods
UNASSIGNED
Synchronous serum and CSF samples were collected from 13 patients. HBV DNA, full-length genome, quasispecies, phylogenetic tree, compartmentalization and mutation of the reverse transcriptase (RT) region were performed based on PCR and sequencing methods.
Results
UNASSIGNED
HBV DNA was detected in the CSF of 3 antiviral-naïve individuals and 1 individual after successful antiviral therapy. Complete full-length HBV genomes were isolated from the CSF of 5 individuals, including 2 with undetectable serum HBV DNA. Ten individuals exhibited distinct CSF-serum quasispecies, 8 harbored independent CSF-serum genetic compartmentalization and phylogenetic trees, and 5 lamivudine/entecavir-associated resistance mutations only in the CSF. The frequencies of rtL180M and rtM204I/V mutations in both serum and CSF were higher in HIV-HBV-coinfected individuals than in the HBV-monoinfected ones (serum: rtL180M: 3.9% vs. 0, P = 0.004; rtM204I/V: 21.3% vs. 0, P < 0.001; CSF: rtL180M: 7.6% vs. 0, P = 0.026; rtM204I/V 7.6% vs. 1.6%, P = 0.097).
Conclusion
UNASSIGNED
CSF is a potential HBV reservoir, and HBV in CSF harbors distinct evolution and mutation characteristics from those in serum. HIV infection increases the possibility of HBV rtL180M and rtM204I/V mutations in both serum and CSF.
Identifiants
pubmed: 37771603
doi: 10.1016/j.jve.2023.100348
pii: S2055-6640(23)00034-1
pmc: PMC10523273
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100348Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Virus Res. 2017 Jan 2;227:88-95
pubmed: 27720823
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2001 Sep;15(3):277-9
pubmed: 11986706
J Neurovirol. 2018 Dec;24(6):769-772
pubmed: 30097971
Clin Pharmacokinet. 2014 Oct;53(10):891-906
pubmed: 25200312
J Gastroenterol Hepatol. 2008 May;23(5):699-706
pubmed: 18410604
Diagn Microbiol Infect Dis. 2019 Dec;95(4):114878
pubmed: 31451314
J Viral Hepat. 2011 Jun;18(6):415-23
pubmed: 20626626
J Clin Virol. 2008 Apr;41(4):301-4
pubmed: 18291715
N Engl J Med. 1986 Feb 20;314(8):518-9
pubmed: 3945282
J Clin Microbiol. 2019 Jul 26;57(8):
pubmed: 31189581
J Gastroenterol Hepatol. 2009 Aug;24(8):1417-23
pubmed: 19486254
Sci Rep. 2020 Sep 30;10(1):16173
pubmed: 32999423
J Virol. 1995 Sep;69(9):5437-44
pubmed: 7636989
J Virol. 2010 Mar;84(5):2395-407
pubmed: 20015984
J Hepatol. 2009 May;50(5):895-905
pubmed: 19304333
Clin Microbiol Infect. 2016 Feb;22(2):201-207
pubmed: 26493847
Clin Microbiol Infect. 2015 Apr;21(4):387.e5-8
pubmed: 25658525
Mol Biol Evol. 2020 Jan 1;37(1):295-299
pubmed: 31504749
Gut. 2015 Dec;64(12):1972-84
pubmed: 26048673
Infection. 2019 Jun;47(3):441-446
pubmed: 30649685
J Hepatol. 2019 Jun;70(6):1093-1102
pubmed: 30794889
Front Public Health. 2021 Apr 26;9:633792
pubmed: 33981663
Curr Top Microbiol Immunol. 2006;299:51-82
pubmed: 16568896
Gastroenterology. 2007 Nov;133(5):1466-74
pubmed: 17915220
J Acquir Immune Defic Syndr. 2012 Apr 1;59(4):376-81
pubmed: 22217676
Biochem Biophys Res Commun. 1987 Jul 31;146(2):452-5
pubmed: 3619890
Curr HIV/AIDS Rep. 2015 Jun;12(2):262-71
pubmed: 25914150
Arch Neurol. 2008 Jan;65(1):65-70
pubmed: 18195140